4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) have been given a consensus rating of “Moderate Buy” by the ten analysts that are presently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and eight have issued a buy recommendation on the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $42.13.

FDMT has been the topic of a number of analyst reports. Cantor Fitzgerald cut shares of 4D Molecular Therapeutics from an “overweight” rating to a “neutral” rating in a report on Monday, September 23rd. Chardan Capital restated a “buy” rating and issued a $39.00 price objective on shares of 4D Molecular Therapeutics in a research report on Thursday, November 14th. Royal Bank of Canada decreased their target price on shares of 4D Molecular Therapeutics from $40.00 to $39.00 and set an “outperform” rating on the stock in a report on Thursday, November 14th. HC Wainwright reissued a “buy” rating and issued a $36.00 price target on shares of 4D Molecular Therapeutics in a report on Thursday, November 14th. Finally, Morgan Stanley assumed coverage on shares of 4D Molecular Therapeutics in a report on Thursday, November 21st. They issued an “underweight” rating and a $8.00 price target on the stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. nVerses Capital LLC bought a new stake in 4D Molecular Therapeutics during the third quarter worth about $40,000. Values First Advisors Inc. purchased a new position in shares of 4D Molecular Therapeutics during the 3rd quarter valued at about $57,000. China Universal Asset Management Co. Ltd. lifted its position in 4D Molecular Therapeutics by 64.6% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,995 shares of the company’s stock worth $108,000 after buying an additional 3,922 shares during the last quarter. Proficio Capital Partners LLC bought a new stake in 4D Molecular Therapeutics in the 3rd quarter worth approximately $108,000. Finally, Quest Partners LLC boosted its stake in 4D Molecular Therapeutics by 17,409.1% in the second quarter. Quest Partners LLC now owns 5,778 shares of the company’s stock worth $121,000 after buying an additional 5,745 shares in the last quarter. 99.27% of the stock is currently owned by hedge funds and other institutional investors.

4D Molecular Therapeutics Stock Up 7.8 %

Shares of NASDAQ:FDMT opened at $7.35 on Friday. The company has a 50-day moving average price of $8.50 and a two-hundred day moving average price of $15.38. 4D Molecular Therapeutics has a twelve month low of $6.77 and a twelve month high of $36.25. The firm has a market capitalization of $339.78 million, a PE ratio of -2.58 and a beta of 2.74.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.